AgomAb Therapeutics NV: director David R Epstein bought 10,000 shares

What happened

• David R Epstein, a director of AgomAb Therapeutics NV, reported two open-market purchases (code P) totaling 10,000 shares: 5,000 shares at $8.57 on Oct 5, 2026 for $42,850 and 5,000 shares at $8.70 on Oct 6, 2026 for $43,500.

Key details

• Transaction dates and prices: Oct 5, 2026 — 5,000 shares at $8.57 ($42,850); Oct 6, 2026 — 5,000 shares at $8.70 ($43,500).
• Total purchased: 10,000 shares for $86,350.
• Transaction code: P (purchase, open market or private purchase as reported).
• Shares owned after the transactions: not reported in the filing.
• Footnote F1: the common shares may be represented by American Depositary Shares, each of which currently represents one common share.
• Filing date and period: filed Oct 7, 2026; period of report Oct 5, 2026. Filing timeliness: not indicated in the filing.

Why it may matter

• These were market purchases (code P), not option exercises or gifts.
• The filing does not show why the insider traded or why the company acted.